ArticleExpert opinion on drug discovery2009
In vitro models of pancreatic cancer for translational oncology research.
Article in Expert opinion on drug discovery, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Four-Dimensional Electrochemiluminescence Microscopy Enables Depth-Resolved Imaging of Single, Living Spheroids.Angewandte Chemie (International ed. in English) · 2026Article
- Bioprinting for drug screening: A path toward reducing animal testing or redefining preclinical research?Bioactive materials · 2025Review
- Experimental models of pancreas cancer: what has been the impact for precision medicine?The Journal of clinical investigation · 2025Review
- Establishment and characterization of a novel ovarian high-grade serous carcinoma cell line-IPO43.Cancer cell international · 2022Article
- Translation of DNA Damage Response Inhibitors as Chemoradiation Sensitizers From the Laboratory to the Clinic.International journal of radiation oncology, biology, physics · 2021Article
- Review
- Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer.Signal transduction and targeted therapy · 2020Review
- Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models.Cancers · 2020Review
- Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients.International journal of molecular sciences · 2020Article
- Chemoradiotherapy screening in a novel biomimetic polymer based pancreatic cancer model.RSC advances · 2019Article
- Article
- Targeting GLI Transcription Factors in Cancer.Molecules (Basel, Switzerland) · 2018Review
- Profiling of different pancreatic cancer cells used as models for metastatic behaviour shows large variation in their N-glycosylation.Scientific reports · 2017Article
- Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells.Molecular cancer therapeutics · 2017Article
- A novel microfluidic 3D platform for culturing pancreatic ductal adenocarcinoma cells: comparison with in vitro cultures and in vivo xenografts.Scientific reports · 2017Article
- Cadmium Exposure as a Putative Risk Factor for the Development of Pancreatic Cancer: Three Different Lines of Evidence.BioMed research international · 2017Review
- Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines.Journal of virology · 2014Article
- Ascites-derived pancreatic ductal adenocarcinoma primary cell cultures as a platform for personalised medicine.British journal of cancer · 2014Article
- A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.Cell cycle (Georgetown, Tex.) · 2014Article
- A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma.Lab on a chip · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPancreatic cancer is a disease of near uniform fatality and the overwhelming majority of patients succumb to their advanced malignancy within a few months of diagnosis. Despite considerable advances in our understanding of molecular mechanisms underlying pancreatic carcinogenesis, this knowledge has not yet been fully translated into clinically available treatment strategies that yield significant improvements in disease free or overall survival.
objectiveCell line-based in vitro model systems provide powerful tools to identify potential molecular targets for therapeutic intervention as well as for initial pre-clinical evaluation of novel drug candidates. Here we provide a brief overview of recent literature on cell line-based model systems of pancreatic cancer and their application in the search for novel therapeutics against this vicious disease.
conclusionWhile in vitro models of pancreatic cancer are of tremendous value for genetic studies and initial functional screenings in drug discovery, they carry several imanent drawbacks and are often poor in predicting therapeutic response in humans. Therefore, in most instances they are successfully exploited to generate hypothesis and identify molecular targets for novel therapeutics, which are subsequently subject to further in-depth characterization using more advanced in vivo model systems and clinical trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.